Abstracts tagged "Oncology"

Abstract Number: 0916 • ACR Convergence 2024
Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia
Mahmut Kaymakci¹, Anuya Natu², Clifford Csizmar², Terra Lasho², Christy Finke², Abhishek Mangaonkar¹, Aref Al-Kali¹, Hassan Alkhateeb¹, Jenna Fernandez², Matthew Koster¹, Cornelia Weyand², Mrinal Patnaik¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
Abstract Number: 2287 • ACR Convergence 2024
Hydroxychloroquine and the Risk of Lymphoma Progression in Sjogren’s Disease: A Retrospective Case Control Study
Christine Xue¹, Monica Guma² and Katherine Nguyen², ¹UC San Diego, San Diego, CA, ²UC San Diego, San Diego
Background/Purpose: Sjogren's disease is an autoimmune disorder characterized by chronic lymphocytic inflammation of the salivary and lacrimal glands. Affected individuals are at heightened risk of…
Abstract Number: 0989 • ACR Convergence 2024
Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
Mark Gibson¹, Benjamin Zuckerman², Maryam Adas¹, Mark Russell³, Katie Bechman¹ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College London, London, England, United Kingdom, ³King's College London, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…
Abstract Number: 1155 • ACR Convergence 2024
Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³ and elvira Diez álvarez⁴, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, Leon
Background/Purpose: Idiopathic inflammatory myopathies (IIM) carry an elevated risk of cancer incidence. Recently published International Guidelines for IIM-associated cancer screening from the Myositis Assessment and…
Abstract Number: 1158 • ACR Convergence 2024
Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients
Sehreen Mumtaz¹, Megan Sullivan², Maximiliano Diaz Menindez³, Emily Craver⁴ and Florentina Berianu⁵, ¹Mayo Clinic, Florida, Jacksonville, FL, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵mayo clinic, Ponte Vedra Beach, FL
Background/Purpose: Nailfold videocapillaroscopy (NVC) findings have been studied to differ in different subsets of myositis-specific autoantibodies (MSAs) associated inflammatory myopathies. Prior investigations observed a statistically…
Abstract Number: 1327 • ACR Convergence 2024
Association of Rheumatoid Arthritis and Frailty Status with Mortality in Patients with Renal Cell Carcinoma
Sherwin Novin¹, Sarah Holt², Maya Swaminathan³, Jonathan Wright², John Gore², Kimme Hyrich⁴, Sizheng Zhao⁵, Jeffrey Sparks⁶, Una Makris⁷, Maria Suarez-Almazor⁸, Petros Grivas², Sarah Psutka² and Namrata Singh⁹, ¹University of Washington, Seattle, WA, ²University of Washington, Seattle, ³MultiCare, Newcastle, WA, ⁴Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁵Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁷UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁸MD Anderson Cancer Center, Houston, TX, ⁹University of Washington, Bellevue, WA
Background/Purpose: Few studies have evaluated clinical outcomes and prognosis of patients with cancer with and without rheumatoid arthritis (RA). Renal cell carcinoma (RCC) is particularly…
Abstract Number: 1678 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
Xavier Sendaydiego¹, Laura Gold², Jean liew³, K Wysham⁴, Maureen Dubreuil⁵, James Andrews¹, Pankti Reid⁶, David Liew⁷, Radjiv Goulabchand⁸, Abha Singh⁹, Grant Hughes¹, Mathilde Pioro¹, Jeffrey Sparks¹⁰, Jeffrey Jarvik², Siddharth Singh⁹ and Namrata Singh¹¹, ¹University of Washington, Seattle, WA, ²Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, ³Boston University, Boston, MA, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁶University of Chicago Medical Center, Chicago, IL, ⁷Austin Health, Heidelberg, Australia, ⁸St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, ⁹University of California San Diego, San Diego, CA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: In the ORAL Surveillance trial, cancer risk was higher among patients with rheumatoid arthritis (RA) on tofacitinib, a Janus kinase inhibitor (JAKi), compared to…
Abstract Number: 2015 • ACR Convergence 2023
Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases
Emmanuel Massy¹, Etienne Mabrut¹, Sabine Mainbourg² and Cyrille Confavreux¹, ¹Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, ²Service de médecine interne et vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69495 Pierre-Bénite, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1; CNRS, UMR 5558, 69622 Villeurbanne, Lyon, France
Background/Purpose: Bone is the third site of metastasis. Bone metastases are associated with poorer survival of patients and impaired quality of life with the occurrence…
Abstract Number: 2127 • ACR Convergence 2023
Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer
Maya Swaminathan¹, Sarah Holt², John Gore², Yaw Nyame², Jonathan Wright², George Schade², Ami Shah³, Jeffrey Sparks⁴, Una Makris⁵, Petros Grivas⁶, Maria Suarez-Almazor⁷, Sarah Psutka² and Namrata Singh⁸, ¹University of Washington, Seattle, WA, ²Department of Urology, University of Washington, Seattle, WA, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶Division of Medical Oncology, Dept. of Medicine, UW; Clinical Research Division; Fred Hutchinson Cancer Center, Seattle, WA, ⁷MD Anderson Cancer Center, Houston, TX, ⁸University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of developing certain cancers, including bladder cancer (Beydon et al. 20231). However, few studies have…
Abstract Number: 2139 • ACR Convergence 2023
Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort
Namrata Singh¹, Aaron Baraff², K Wysham³, Punyasha Roul⁴, Grant Cannon⁵, Brian Sauer⁶, Geoffrey Thiele⁴, Bryant England⁴, Ted R Mikuls⁷ and Joshua Baker⁸, ¹University of Washington, Bellevue, WA, ²VA Puget Sound Seattle, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: A prior study suggested a higher risk of cancer mortality in patients with rheumatoid arthritis (RA) with higher levels of circulating leptin, an adipocytokine…
Abstract Number: 2512 • ACR Convergence 2023
Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis
Jacques-Eric Gottenberg¹, Nathanaël Sedmak², Pierre Tran Ba Loc², Thibaut Fabacher², Thibaut Bahougne², Cécile Arnold², Guillaume Desjeux³, Hervé Servy⁴, Nicolas Meyer², Erik Sauleau², Raphaele Seror⁵ and Eden Sebbag⁶, ¹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³e-Health Services Sanoia, Gemenos, France, ⁴e-Health Services Sanoia, La Ciotat, France, ⁵University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁶Université de Strasbourg, Strasbourg, France
Background/Purpose: In about 10% of patients, the immune response to immune checkpoint inhibitors (ICI) exceeds the anti-tumor response and leads to autoimmune complications (immune-related Adverse…
Abstract Number: 2513 • ACR Convergence 2023
Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Laura Cappelli¹, Jamie Perin², Clifton Bingham³ and Ami Shah⁴, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: : Immune checkpoint inhibitors (ICI) for cancer treatment can cause inflammatory arthritis (IA). ICI-IA is a heterogeneous entity affecting peripheral joints, tendons, and rarely…
Abstract Number: 2514 • ACR Convergence 2023
Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis
Selene Rubino¹, Grant Cannon², Brian Sauer³, Jorge Rojas Jr⁴, Greg Stoddard¹, Gary Kunkel¹, Jessica A Walsh⁵, Bryant England⁶, Ted R Mikuls⁷, Joshua Baker⁸ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴Puget Sound VA and University of Utah, Seattle, WA, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Myositis is an infrequent but serious complication associated with immune check point inhibitor (ICI) treatment. Many patients with ICI-induced myositis will develop concurrent myocarditis…
Abstract Number: 0016 • ACR Convergence 2023
Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: TP53, a tumor-suppressor protein known as the guardian of the genome, plays a critical role in regulating genomic stability and cellular function. When TP53…
Abstract Number: 0072 • ACR Convergence 2023
Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons
Marie Naingeon¹, Samuel Bitoun², Matthieu roulleaux Dugage¹, Caroline de Oliveira¹, Caroline Berthot¹, Xavier Mariette³, Nathalie Chaput¹ and Gaetane Nocturne⁴, ¹LIO, Department of Medicine, Gustave Roussy Université Paris Saclay, Villejuif, France, ²CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ³Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁴APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Immunosenescence is a global remodeling of immune functions that has been first described with aging. It can also occur in pathologies associated with chronic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.